MT-7117
Sponsors
Tanabe Pharma Corporation, Tanabe Pharma America, Inc.
Conditions
Diffuse Cutaneous Systemic SclerosisEPPHealthyHealthy SubjectsHealthy VolunteerMild and Moderate Hepatic ImpairmentNormal Renal FunctionRenal Impairment
Phase 1
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects
CompletedNCT02834442
Start: 2016-07-31End: 2017-06-30Updated: 2017-07-25
Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor
CompletedNCT03688022
Start: 2018-10-25End: 2018-12-22Updated: 2023-05-15
Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function
CompletedNCT04116476
Start: 2019-08-01End: 2021-02-16Updated: 2023-05-15
PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function
CompletedNCT04656795
Start: 2020-12-02End: 2021-12-09Updated: 2023-05-15
Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects
CompletedNCT04793295
Start: 2021-03-23End: 2022-02-04Updated: 2023-05-15
Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects
CompletedNCT05241535
Start: 2022-01-12End: 2022-02-27Updated: 2023-05-15
The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects.
CompletedNCT06994286
Start: 2025-06-24End: 2025-08-04Updated: 2026-04-03